Lysophospholipids and cancer: current status and perspectives

被引:9
|
作者
Raynal, P [1 ]
Montagner, A [1 ]
Dance, M [1 ]
Yart, A [1 ]
机构
[1] Hop Purpan, Ctr Physiopathol Toulouse Purpan, INSERM,LML, U563,IFR 30,Dept Lipoprot & Mediateurs Lipidiques, F-31059 Toulouse, France
来源
PATHOLOGIE BIOLOGIE | 2005年 / 53卷 / 01期
关键词
lysophosphatidic acid; cancer; oncolipid; growth factor; autotaxin; sphingosine; 1-phosphate;
D O I
10.1016/j.patbio.2004.01.005
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Circulating phospholipids carrying a single esterified fatty acid, the so-called lysophospholipids, are no,,v considered as mediators of the intercellular communication. Their major members are the lysophosphatidic acid and the sphingosine I-phosphate. two molecules displaying biological activities similar to those of growth factors or cytokines, through a recently identified subfamily of G protein-coupled receptors. They are involved in various biological processes, e.g., brain development and angiogenesis. but the following evidences suggest that these. lipids are also significant actors of tumour development: (i) they stimulate the growth, survival and migration of tumour cells from various origins (ovary, prostate, glioblastoma...); (ii) they are abundant in malignant effusions; (iii) the lysophospholipid-producing enzymes are tumourigenic. Even if it remains necessary to define the role of these "oncolipids" in relationship with oncogenes and tumor suppression, they may well be the mediators of an efficient autostimulatory system of the proliferating and migratory capacities of cancer cells, suggesting that lysophospholipids could represent novel valuable targets for anticancer pharmacology. (C) 2004 Elsevier SAS. Tous droits reserves.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 50 条
  • [31] Cancer Management in Sudan: Current Status and Future Perspectives
    Abuidris, Dafalla Omer
    Ahmed, Anas Osman
    Elmadani, Ahmed Elkhidir
    Eltayeb, Elgaylani Abdalla
    Elgaili, Elgaili Mohamed
    Elwali, Nasreldin Abdalla
    Hamed, Kamal Eldein
    SUDAN JOURNAL OF MEDICAL SCIENCES, 2009, 4 (02): : 189 - 193
  • [32] Current Status and Future Perspectives in Differentiated Thyroid Cancer
    Kim, Tae Yong
    Kim, Won Gu
    Kim, Won Bae
    Shong, Young Kee
    ENDOCRINOLOGY AND METABOLISM, 2014, 29 (03) : 217 - 225
  • [33] Current Status of Immunotherapy for Lung Cancer and Future Perspectives
    Kim, Ho Cheol
    Choi, Chang-Min
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2020, 83 (01) : 14 - 19
  • [34] Current status and future perspectives in gastric cancer management
    Roukos, DH
    CANCER TREATMENT REVIEWS, 2000, 26 (04) : 243 - 255
  • [35] MicroRNAs in cancer biology and therapy: Current status and perspectives
    Price, Colles
    Chen, Jianjun
    GENES & DISEASES, 2014, 1 (01) : 53 - 63
  • [36] PARP Inhibitors in Endometrial Cancer: Status and Perspectives Current
    Musacchio, Lucia
    Caruso, Giuseppe
    Pisano, Carmela
    Cecere, Sabrina Chiara
    Di Napoli, Marilena
    Attademo, Laura
    Tambaro, Rosa
    Russo, Daniela
    Califano, Daniela
    Palaia, Innocenza
    Muzii, Ludovico
    Panici, Pierluigi Benedetti
    Pignata, Sandro
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6123 - 6135
  • [37] Cancer biomarker discovery: Current status and future perspectives
    Maebert, Katrin
    Cojoc, Monica
    Peitzsch, Claudia
    Kurth, Ina
    Souchelnytskyi, Serhiy
    Dubrovska, Anna
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2014, 90 (08) : 659 - 677
  • [38] Current status and perspectives of brachytherapy for head and neck cancer
    Hitoshi Shibuya
    International Journal of Clinical Oncology, 2009, 14
  • [39] Prostate cancer screening: current status and future perspectives
    Strope, Seth A.
    Andriole, Gerald L.
    NATURE REVIEWS UROLOGY, 2010, 7 (09) : 487 - 493
  • [40] Triple negative breast cancer: Current status and perspectives
    Le Du, Fanny
    Moati, Emilie
    Vaflard, Pauline
    Bailleux, Caroline
    Pierga, Jean-Yves
    Dieras, Veronique
    BULLETIN DU CANCER, 2025, 112 (01) : 82 - 99